Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | ACP3 | P15309 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | ALPG | P10696 | 1/20 | 0.31 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8625379 | 0.87 | PPARA (0.38) | LAP3ANPEPACP3PPARGPPARA | |
| SCHEMBL8618813 | 0.85 | PPARA (0.37) | LAP3ANPEPPPARGPPARA | |
| SCHEMBL8947039 | 0.84 | LAP3 (0.36) | LAP3ANPEPACP3PTK2B | |
| SCHEMBL8947013 | 0.83 | HTR2A (0.35) | LAP3ANPEPACP3 | |
| SCHEMBL8947080 | 0.82 | AKR1C3 (0.35) | LAP3ANPEPACP3PIN1PPARG | |
| SCHEMBL8623433 | 0.82 | SCN4A (0.39) | LAP3ANPEPACP3PIN1PPARG | |
| SCHEMBL9167366 | 0.82 | ADRA2C (0.38) | LAP3ANPEPACP3TSHR | |
| SCHEMBL8625231 | 0.79 | ACP3 (0.47) | LAP3ANPEPACP3PPARGPPARA | |
| SCHEMBL8620463 | 0.79 | FDFT1 (0.38) | LAP3ANPEPACP3PIN1PPARG | |
| SCHEMBL8618892 | 0.78 | LAP3 (0.43) | LAP3ANPEPACP3PIN1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | claimed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | claimed |
| US-5610314-A | Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |